

Applicants: Anderson, et al  
U.S.S.N.: 10/635,398

## REMARKS

In response to the Restriction Requirement mailed March 16, 2005, applicants elect Group IX, claims 20-28 and 36-45. Further, applicants elect the nucleic acid sequence of SEQ ID NO:35 (a.k.a., NOV2f; CG101826-01; Adenylate kinase 5).

Support for the utility of the claimed invention can be found, for example, on pages 214-221 of the specification. A relevant priority document for the elected sequence is Provisional Patent Application US Ser. No. 60/296404, filed June 6, 2001.

Claims 1-19, and 29-35 have been canceled herein without prejudice as drawn to non-elected subject matter. Applicants reserve the right to pursue these claims in a later application.

Furthermore, claims 22, 24, 25 and 41-45 have been canceled herein.

Claims 20, 23, and 36 have been amended to reflect the sequence election. No new matter has been added.


Upon entry of this amendment, claims 20-21, 23, 26-28 and 36-40 will be pending

Applicants: Anderson, et al  
U.S.S.N.: 10/635,398

### CONCLUSION

On the basis of the foregoing remarks, Applicants respectfully submit that this paper is fully responsive and that the pending claims are in condition for allowance. Such action is respectfully requested. If there are any questions regarding this response, the Examiner is encouraged to contact the undersigned at the telephone number provided below.

Respectfully submitted on this 18th Day of April, 2005



Daniel K. Rieger

Registration No. 56,436

CuraGen Corporation  
555 Long Wharf Drive  
New Haven, CT 06511  
Telephone: (203) 974-6271  
Facsimile (203) 401-3351